Alcon vs Royalty Pharma

Alcon (ALC), health care, and Royalty Pharma (RPRX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Royalty Pharma is worth $39.5B on the stock market and Alcon $35.6B: Royalty Pharma is valued at 11% more. Alcon trades at 53.7 times earnings and Royalty Pharma at 44.9; operating margins in their latest fiscal years were 13.1% and 65.6%. Over the past year Alcon's share price has moved -2.82% and Royalty Pharma's +73.7%.

Key facts

Alcon market value
$35.6B
Royalty Pharma market value
$39.5B
Alcon P/E
53.7
Royalty Pharma P/E
44.9
Alcon revenue
$10.4BFY to 2025-12-31
Royalty Pharma revenue
$2.4BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Alcon vs Royalty Pharma: every measure side by side
Measure Alcon Royalty Pharma
SectorHealth CareHealth Care
Country Switzerland United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$35.6Blower$39.5Bhigher
Revenue$10.4Bhigher$2.4Blower
Earnings$980Mhigher$770.9Mlower
Employees25,942higher100lower
Total assets$31.6Bhigher$19.6Blower
Valuation
P/E53.7higher44.9lower
P/S3.4lower16.6higher
P/B—4.5
Dividend yield—1.35%
Profitability
Operating margin13.1%lower65.6%higher
Balance sheet
Net assets$22Bhigher$9.7Blower
Total liabilities$9.5Blower$9.9Bhigher
Total debt$4.7Blower$9Bhigher
Cash on hand$1.5Bhigher$618.7Mlower
Price change
Today+0.64%higher+0.23%lower
1 year-2.82%lower+73.7%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns ALC · Who owns RPRX

Further comparisons

Learn

Questions and answers

Which is bigger, Alcon or Royalty Pharma?

By market value, Royalty Pharma is the larger: $39.5B against $35.6B for Alcon. By revenue in its latest fiscal year, Alcon is the larger: $10.4B against $2.4B for Royalty Pharma.

Which has the higher P/E ratio?

Alcon: 53.7, against 44.9 for Royalty Pharma. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Royalty Pharma: 65.6%, against 13.1% for Alcon. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Royalty Pharma: $9B, against $4.7B for Alcon. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Alcon and Royalty Pharma?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Alcon and 5 hold Royalty Pharma.

Cite this page

Funkfolio, “Alcon vs Royalty Pharma”, data as of 18 November 2026. https://funkfolio.com/compare/alc-vs-rprx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.